CNSP (CNS Pharmaceuticals) Total Operating Expense: $16.62 Mil (TTM As of Mar. 2026)


CNSP CNS Pharmaceuticals Inc CNSP
30 GF Score
Price $5.17
! 1 Warning Sign
View Full Analysis

What is CNS Pharmaceuticals Total Operating Expense?

CNS Pharmaceuticals CNSP -2.91% 30 Total Operating Expense is $16.62 Mil as of Mar. 2026. GuruFocus rates CNSP with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

CNS Pharmaceuticals's Total Operating Expense for the three months ended in Mar. 2026 was $4.98 Mil. CNS Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $16.62 Mil.

CNS Pharmaceuticals Total Operating Expense Related Terms

CNS Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for CNS Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNS Pharmaceuticals Total Operating Expense Chart

CNS Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only 14.49 15.27 18.87 14.90 15.99

CNS Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.34 2.41 3.25 5.99 4.98
CNSP
30GF Score
CNS Pharmaceuticals Inc CNSP
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CNS Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $16.62 Mil mean?
CNS Pharmaceuticals (CNSP) has a Total Operating Expense of $16.62 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on CNS Pharmaceuticals and its competitors.
Is CNS Pharmaceuticals' Total Operating Expense too high?
CNS Pharmaceuticals' current Total Operating Expense is $16.62 Mil. Overall, CNS Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does CNS Pharmaceuticals' Total Operating Expense compare to NXTC and ENVB?
CNS Pharmaceuticals' Total Operating Expense of $16.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on CNS Pharmaceuticals and its competitors. CNS Pharmaceuticals's current Total Operating Expense is $16.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNS Pharmaceuticals stock overvalued right now?
CNS Pharmaceuticals (CNSP) has a current Total Operating Expense of $16.62 Mil. The current Total Operating Expense is $16.62 Mil. CNS Pharmaceuticals' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For CNS Pharmaceuticals (CNSP), the current Total Operating Expense is $16.62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CNS Pharmaceuticals Business Description

Address 2100 West Loop South, Suite 900, Houston, TX, USA, 77027
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
30GF Score

Get the complete analysis for CNSP

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.17
Price